[1]
|
B. J. Unde, “Pharmacotherapy of asthma,” In: L. L. Brunton, J. S. Lazo, K. L. Parker, Eds., Goodman & Gil- man’s, The pharmacological basis of therapeutics., Mc- graw-Hill medical publishing division, New York, 2006, pp. 897-934.
|
[2]
|
C. M. Spencer, D. McTavish, “Budesonide: a review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease,” Drugs, Vol. 50, 1995, pp. 854-72.
|
[3]
|
R. N. Brogden, D. McTavish, “Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis,” Drugs, Vol. 44, 1998, pp. 375-407,
|
[4]
|
G. Jeffrey, et al., “Have done budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose ranging study,” Current Therapy, Vol. 22, 2005, 23-27.
|
[5]
|
N. Mygind, T. J. H. Clark, “Topical steroid treatment for asthma and rhinitis” In: B. Tindall, Inc., London, 1980, pp. 89, 91,152,159,172.
|
[6]
|
K. Masuyama, et al., “Glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis,” Immunology, Vol. 82, 1994, pp. 192-99.
|
[7]
|
N. S. Chandrashekar, R. H. Shobha Rani, “Design, fabri- cation and calibration of modified Franz diffusion cell for transdermal diffusion studies,” International Journal of Pharmaceutical excipients. October-November 2005, pp. 104-106.
|
[8]
|
J. Eliassaf, “Detection of small quantity of Poly(vinyl alcohol) in poly(vinyl chloride) resins,” Polym. Lett., Vol.16, 1972, pp. 225-235.
|
[9]
|
S. P. Gupta, S. K. Jain, “Development of matrix-mem- brane transdermal drug delivery system for atenolol,” Drug Delivery, Vol. 11, 2004, pp. 281-286.
|
[10]
|
P. R. P. Verma, S. S. Iyer, “Transdermal Delivery of propranolol using mixed grades of Eudragit: Design and in vitro and in vivo evaluation,” Drug dev. Ind. Pharm., Vol. 26, No. 4, 2000, pp. 471-476.
|
[11]
|
R. Krishna, J. K. Pandit, “Transdermal delivery of pro- pranolol,” Ind. Pharm., Vol. 20, No. 15, 1994, pp. 2459- 2465.
|
[12]
|
P. Arora, B. Mukherjee, “Design, Development, Phys- icochemical and in vitro and in vivo Evaluation of Transdermal Patches containing Diclofenac diethylam- monium salt,” J. Pharm. Sci., Vol. 91, 2002, pp. 2076- 2089.
|
[13]
|
United States Pharmacopoeia, “Physical tests <711> Dissolution,” Vol. 24, 2000, pp. 1941.
|
[14]
|
M. Siewert, J. Dressman, C. K. Brown, V. P. Shah, “FIP/ AAPS Guidelines to Dissolution / in vitro release testing of novel / special dosage forms,” AAP Spharmscitech, Vol. 4, No. 1, Article 7. 2003, pp. 1-10.
|
[15]
|
C. Valenta, B. G. Auner, “The use of polymers for dermal and transdermal delivery,” European Journal of Pharma- ceutical Sciences. Vol. 58, 2004, pp. 279-289.
|
[16]
|
P. Costa, “Modeling and comparison of dissolution pro- files,” Eur. J. Pharm. Sci. Vol. 13, 2001, pp. 123-133.
|
[17]
|
J. Singh, H. I. Maibach, “Irritancy of Topical Chemicals and Transdermal Delivery Systems,” Drug Pharm. Sci. Vol. 1, 2001, pp. 281-296.
|
[18]
|
A. C. Calpena, E. Escribano, H. San Martin, “Influence of formulation on the in vitro transdermal penetration of sodium Diclofenac,” Arzneimittle Forschung Drug Research, Vol. 49, No. 11, 1999, pp. 1012-1017.
|